Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mass malaria drug campaign aims to stop parasite spread in senegal

NCT ID NCT07281443

Prevention Sponsor: Institut de Recherche pour le Developpement Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving antimalarial drugs to entire communities can reduce malaria transmission. About 18,000 people in 50 villages in Senegal will take part. The goal is to clear hidden malaria parasites that standard treatments miss, especially during the dry season.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 18,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 months to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Randomisation unit : cluster, defined as village or group of eligible villages \<3km from each other VILLAGE-LEVEL CRITERIA Inclusion * in Kedougou health district * population \<1500 inhabitants * \>5km from international border * \>3km from a town with 1500 inhabitants or higher * \>3km from another village/cluster Exclusion * village inaccessible during rainy season * village without community health worker and impossible to set up one INDIVIDUAL-LEVEL: MDA with DHA-piperaquine and single low dose primaquine Inclusion * consent (+ assent for youth aged 12-17) * age \>=3 months * in the village for \>=4 days at time of MDA initiation * not pregnant (women 15-49 years with negative pregnancy test or under contraception) Exclusion (excluded from DHA-piperaquine and primaquine) * allergy to artemisinin combination therapy * pregnant women (referred for administration of IPTp) or women without pregnancy test result * presenting with acute disease symptoms: in case of fever or history of fever, individuals will be tested with RDT and, if positive, refered to CHW or healthpost for symptomatic malaria treatment according to national guidelines. Exclusion (excluded from primaquine only, eligible for DHA-p) * children aged 3-6 months * lactating women INDIVIDUAL-LEVEL: youth-targeted testing and treatment activity Inclusion * age 15-24 (+ assent for youth aged 15-17) * consent Exclusion * none. in case of RDT-positivity, participants will be referred for treatment according to national guidelines (recommendation of treatment in case of a positive test, irrespective of symptoms). COHORT STUDY 8 villages/clusters selected for an in-depth cohort study Household inclusion * consent of head of household * not planning to move out of study village * 50% of more members aged \>=15 years agree to participate Individual participant inclusion * household member or visitor staying longer than 1 night * consent (+ assent for youth aged 12-17) * age \>=6 months Individual participant exclusion * in another study on malaria or health

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria falciparum are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malaria parasitemia Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malaria falciparum Malaria, asymptomatic parasitaemia

Contacts and locations

Locations

  • District de Santé de Kédougou - Kedougou Health District

    Kedougou, Senegal

More trials for these conditions

Other studies related to the condition(s) this trial covers.